Skip to main content
ConductScienceScienceDex

Ozgur Sahin

NIH Rank #7359
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 11262365Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Biochemistry

NIH Funding · FY2024

Linked Award Amount
$1.7M
Full award amounts, FY2024
Award Records
3
Records listing this PI
Award-Linked Rank
#7,359
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Ozgur Sahin. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Ozgur Sahin as a PI. Multi-PI records show the full award amount for context.

  • 4R42CA275622-02R42
    Developing novel LOX inhibitors to target chemotherapy resistant TNBC
    Loxigen, Inc.
    $992.9K
    award amount
  • 5R01CA267101-04R01
    Overcoming chemoresistance in triple negative breast cancer
    Medical University of South Carolina
    $352.3K
    award amount
  • 5R01CA251374-04R01
    Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
    Medical University of South Carolina
    $321.8K
    award amount

Award organizations

Organizations that administered FY2024 awards listing Ozgur Sahin as a PI.

Loxigen, Inc.
SC
$992.9K
1 grant
Medical University of South Carolina
SC
$674.1K
2 grants

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Loxigen, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #7359
  5. 2025
    $2M Cumulative Funding
  6. 2025
    Multi-Institutional Research
    Awards at 2 institutions
  7. 2025
    R01 Grant Holder

Explore further

Find collaborators for Ozgur Sahin

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →